Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.

about

Abscisic Acid: A Novel Nutraceutical for Glycemic Control.

P2860

Q33790397-2457EC5E-3895-4100-8C49-A31B01754434

P2860

Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.

Item

http://www.wikidata.org/entity/Q38702260

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.

@en

type

Item

label

Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.

@en

prefLabel

Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.

@en

P1476

Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.

@en

P2093

Ashish Sarraju

http://www.w3.org/2001/XMLSchema#string

Joshua W Knowles

http://www.w3.org/2001/XMLSchema#string

P2860

Glucagon-like peptide analogues for type 2 diabetes mellitus

Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.

Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.

Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization.

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

P2888

s11883-016-0558-5

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11883-016-0558-5

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sun H. Kim

P577

2016-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047744067

http://www.w3.org/2001/XMLSchema#string

P698

26782825

http://www.w3.org/2001/XMLSchema#string

Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.

about

P2860

P2860

Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698